Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403283 · ClinicalTrials.gov registry record
Dyslipidemia and Diabetic Retinopathy
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 45
- Enrollment target
NCT03403283 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 45 participants.
The verdict
NCT03403283 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the reparative cells of blood vessels called endothelial progenitor cells(EPC) are defective in people with diabetes.
Interventions
- OTHER 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy
- OTHER Healthy Controls 15 age matched control subjects
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-01 |
| Est. Completion | 2023-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03403283
The ClinicalTrials.gov registry entry for NCT03403283 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy is the first listed.
NCT03403283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03403283 about?
NCT03403283 is a clinical study titled "Dyslipidemia and Diabetic Retinopathy". The purpose of this study is to determine if the reparative cells of blood vessels called endothelial progenitor cells(EPC) are defective in people with diabetes.
What is the current status of trial NCT03403283?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2014-01. Estimated completion is 2023-04-30.
What interventions are being tested in trial NCT03403283?
The interventions under investigation include: 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy (OTHER), Healthy Controls 15 age matched control subjects (OTHER).
Who is sponsoring clinical trial NCT03403283?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.